Eltrombopag for Peripheral Blood Stem Cell Harvest
Recruiting
Phase 2
Interventional Study
Lymphoma
Peripheral Blood Stem Cell Transplantation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 46 (estimated)
- Sponsor
- National Taiwan University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to explore the activity of eltrombopag in lymphoma patients receiving autologous hematopoietic stem cell harvest. The main questions it aims to answer are:
* Determine the efficacy of adding eltrombopag during autologous hematopoietic stem cell mobilization and harvest.
* Determine the pharmacokinetics and pharmacodynamics of serum eltrombopag concentration, cir…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age: ≥ 18 years
* Diagnosis: Hodgkin lymphoma or non-Hodgkin lymphoma
* Disease status: complete response, partial response, or stable disease after at least 2 cycles of treatment (see appendix 2 for definition)
* Planned to receive ESHAP (etoposide, steroid, high-dose cytarab…
Contacts